摘要
Objective: To studied the effect of Diethyldithiocarbamate (DDC) on the antitumor activity of adriamycin (ADM) nanoparticle-lipiodol emulsion. Methods: The SD rats bearing liver carcinoma were divided into six groups and treated by saline, adriamycin, adriamycin nanoparticle-lipiodol emulsion, adriamycin liposome-lipiodol emulsion, DDC plus adriamycin nanoparticle-lipiodol emulsion, DDC plus adriamycin liposome-lipiodol emulsion respectively. The volume of the tumors, tumor growth rate (G%) and life prolonging rate PL% in six groups were determined. Results: The values of the IC50 (μg/ml) of adriamycin were reduced from 18.40 to 0.74 for the resistant cells SGC7901/CVR, and from 4.00 to 0.32 for the sensitive cells SGC7901/WT by pretreating the tumor cells with DDC. The tumor growth rate (G%) and life prolonging rate PL% increased significantly (P<0.05) in the DDC pretreated groups than adriamycin nanoparticle-lipiodol or adriamycin liposome-lipiodol emulsion groups. Conclusion: The antitumor effect of adriamycin can be enhanced by inhibiting the superoxide dismutase (SOD) in tumor cells by DDC.
Objective: To studied the effect of Diethyldithiocarbamate (DDC) on the antitumor activity of adriamycin (ADM) nanoparticle-lipiodol emulsion. Methods: The SD rats bearing liver carcinoma were divided into six groups and treated by saline, adriamycin, adriamycin nanoparticle-lipiodol emulsion, adriamycin liposome-lipiodol emulsion, DDC plus adriamycin nanoparticle-lipiodol emulsion, DDC plus adriamycin liposome-lipiodol emulsion respectively. The volume of the tumors, tumor growth rate (G%) and life prolonging rate PL% in six groups were determined. Results: The values of the IC50 (μg/ml) of adriamycin were reduced from 18.40 to 0.74 for the resistant cells SGC7901/CVR, and from 4.00 to 0.32 for the sensitive cells SGC7901/WT by pretreating the tumor cells with DDC. The tumor growth rate (G%) and life prolonging rate PL% increased significantly (P<0.05) in the DDC pretreated groups than adriamycin nanoparticle-lipiodol or adriamycin liposome-lipiodol emulsion groups. Conclusion: The antitumor effect of adriamycin can be enhanced by inhibiting the superoxide dismutase (SOD) in tumor cells by DDC.
基金
This work was supported by the National Natural Science Foundation of China (No. 39390191
No. 30170271)
